Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06048146CT.gov A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis | — | Completed | — | — | — |
NCT04080843CT.gov Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rectal Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxaliplatin (this asset) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2 | CCC · 54 |
| pf-08634404 | Pfizer | P3 | B |
| Capecitabine | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2 | B |
| Catequentinib | Zhejiang University | P2 | B |
| Desmopressin | Laboratorio Elea Phoenix S.A. | P2 | NR |
Other indications for Oxaliplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 76 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
| Colorectal Neoplasm | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oxaliplatin in Rectal Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oxaliplatin-rectal-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →